Last reviewed · How we verify

NCT03981562

Vitamin D and Hereditary Haemorrhagic Telangiectasia

Status unknown Phase 2 Last updated 11 June 2019
What this trial tests

Phase 2 trial testing Vit D in Hereditary Haemorrhagic Telangiectasia in 60 participants. Status unknown.

Timeline
16 July 2018
Primary endpoint
1 July 2020
1 September 2020

Quick facts

Lead sponsorSt. Paul's Hospital, Canada
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment60
Start date16 July 2018
Primary completion1 July 2020
Estimated completion1 September 2020
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

St. Paul's Hospital, Canada

Who can join

19 and older, any sex, with Hereditary Haemorrhagic Telangiectasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to assess whether supplementing vitamin D in patients diagnosed with Hereditary Haemorrhagic Telangiectasia (HHT) will decrease the frequency and severity of nosebleeds these patients experience. It is hypothesized that the larger the dose of daily vitamin D given to the patients, the less frequent and less severe the nosebleeds will be.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding.
    Albiñana V, Cuesta AM, Rojas-P I, Gallardo-Vara E, et al · · 2020 · cited 20× · PMID 32517280 · DOI 10.3390/jcm9061766

Verify or expand the search:

Other trials of Vit D

Trials testing the same drug.

Other recruiting trials for Hereditary Haemorrhagic Telangiectasia

Currently open trials in the same condition.

Other St. Paul's Hospital, Canada trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03981562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing